Bar Plot from Scientific Research

Flow cytometry-based measurable residual disease (MRD) positive rates in the TARGET-AML patients at the end of the first cycle of chemotherapy regimen. A patient was defined as MRD-positive if the MRD level was equal to or greater than 0.1%.

DOI